The value of inflammatory markers to diagnose and monitor diabetic foot osteomyelitis

Suzanne A.V. Van Asten, Adam Nichols, Javier La Fontaine, Kavita Bhavan, Edgar J.G. Peters, Lawrence A. Lavery

Research output: Contribution to journalArticleAcademicpeer-review

56 Citations (Scopus)


In this study, we assessed the effectiveness of inflammatory markers to diagnose and monitor the treatment of osteomyelitis in the diabetic foot. We evaluated 35 consecutive patients admitted to our hospital with infected foot ulcers. Patients were divided in two groups based on the results of bone culture and histopathology: osteomyelitis and no osteomyelitis. The erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor alpha (TNFα), monocyte chemotactic protein-1 (MCP-1) and macrophage inflammatory protein-1 alpha (MIP1α) were measured at baseline after 3 and 6 weeks of standard therapy. PCT levels in the osteomyelitis group were significantly higher at baseline than in the group with no osteomyelitis (P = 0·049). There were no significant differences between the two groups in the levels of the other markers. CRP, ESR, PCT and IL-6 levels significantly declined in the group with osteomyelitis after starting therapy, while MCP-1 increased (P = 0·002). TNFα and MIP1α levels were below range in 80 out of 97 samples and therefore not reported. Our results suggest that PCT might be useful to distinguish osteomyelitis in infected foot ulcers. CRP, ESR, PCT and IL-6 are valuable when monitoring the effect of therapy.

Original languageEnglish
Pages (from-to)40-45
Number of pages6
JournalInternational wound journal
Issue number1
Publication statusPublished - 1 Feb 2017


  • Biomarkers
  • Diabetic foot infection
  • Erythrocyte sedimentation rate
  • Osteomyelitis
  • Procalcitonin

Cite this